Table 3.
Anti-interleukin and interleukin agents with clinical data for psoriasis treatment.
| Target | Medications | Type of psoriasis | Trials | Results |
|---|---|---|---|---|
| IL-1 | Gevokizumab | GPP | Case reports | Responsive |
| Canakinumab | GPP, PPPP | Case reports | GPP: responsive; PPPP: lack of response | |
| IL-1R | Anakinra | GPP, PPPP | Case reports | GPP: responsive; PPPP: partial response |
| IL-2 | DAB389IL-2 | Plaque-type psoriasis | Phase II, terminated | Serious adverse events |
| IL-2R | Basiliximab | GPP, plaque-type psoriasis | Case reports | Responsive |
| Daclizumab | Plaque-type psoriasis | Phase I | Responsive | |
| IL-6R | Tocilizumab | PPPP | Case reports | Responsive |
| IL-8 | Abcream (Enboke) |
Plaque-type psoriasis | Phase III | On market |
| ABX- IL8 | Plaque-type psoriasis | Phase IIb, terminated | Lack of efficacy | |
| IL-10 agonist | Recombinant human IL-10 | Plaque-type psoriasis | Phase II, terminated | Lack of efficacy |
| IL-20 | NNC0109-0012 | Plaque-type psoriasis | Phase I, terminated | Lack of efficacy |
| IL-22 | Fezakizumab (ILV-094) | Plaque-type psoriasis | Phase I, terminated | Lack of efficacy |
| ILV-095 | Plaque-type psoriasis | Phase I, terminated | Lack of efficacy | |
| Dual targets | ||||
| IL-17A and TNF-α | COVA 322 | Plaque-type psoriasis | Phase Ib/IIa, terminated |
Safety issue |
R, receptor; IL, interleukin; GPP, generalized pustular psoriasis; PPPP, palmoplantar pustular psoriasis; TNF-α, tumor necrosis factor alpha.